FDA approved Xocova (ensitrelvir) as the first oral option for post-exposure prophylaxis of COVID-19, expanding the preventive toolkit beyond vaccines and the high-risk-only monoclonal antibody pemivibart.
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi \&; Co
